Arcus Biosciences, Inc. (RCUS)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Total revenues | 160 | - | 48 | 39 |
| Research and development (includes 11, (14), 6 and (30) from a related party) | 139 | - | 123 | 115 |
| Impairment of long-lived assets | - | - | - | - |
| General and administrative (includes 2, , 2, and from a related party) | 29 | - | 30 | 30 |
| Total operating expenses | 168 | - | 153 | 145 |
| Loss from operations | -8 | -122 | -105 | -106 |
| Interest expense | 2 | 1 | 1 | - |
| Interest and other income, net | 10 | 11 | 14 | 13 |
| Total non-operating income, net | 8 | 10 | 13 | 13 |
| Income (loss) before income taxes | - | -112 | -92 | -93 |
| Income tax expense | - | - | - | - |
| Net income (loss) | - | -112 | -92 | -93 |
| Basic (in dollars per share) | - | -1.14 | -1 | -1.02 |
| Basic (in shares) | 106,100,000 | 98,400,000 | 91,400,000 | 91,100,000 |
| Diluted (in dollars per share) | - | -1.14 | -1 | -1.02 |
| Diluted (in shares) | 106,500,000 | 98,400,000 | 91,400,000 | 91,100,000 |